A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals by Anthony Ajua et al.
Ajua et al. Malaria Journal 2012, 11:367
http://www.malariajournal.com/content/11/1/367METHODOLOGY Open AccessA flow cytometry-based workflow for detection
and quantification of anti-plasmodial antibodies
in vaccinated and naturally exposed individuals
Anthony Ajua1,2, Thomas Engleitner1, Meral Esen1,2, Michael Theisen3,4, Saadou Issifou2
and Benjamin Mordmüller1,2*Abstract
Background: Antibodies play a central role in naturally acquired immunity against Plasmodium falciparum. Current
assays to detect anti-plasmodial antibodies against native antigens within their cellular context are prone to bias
and cannot be automated, although they provide important information about natural exposure and vaccine
immunogenicity. A novel, cytometry-based workflow for quantitative detection of anti-plasmodial antibodies
in human serum is presented.
Methods: Fixed red blood cells (RBCs), infected with late stages of P. falciparum were utilized to detect
malaria-specific antibodies by flow cytometry with subsequent automated data analysis. Available methods for
data-driven analysis of cytometry data were assessed and a new overlap subtraction algorithm (OSA) based on
open source software was developed. The complete workflow was evaluated using sera from two GMZ2 malaria
vaccine trials in semi-immune adults and pre-school children residing in a malaria endemic area.
Results: Fixation, permeabilization, and staining of infected RBCs were adapted for best operation in flow
cytometry. As asexual blood-stage vaccine candidates are designed to induce antibody patterns similar to those in
semi-immune adults, serial dilutions of sera from heavily exposed individuals were compared to naïve controls to
determine optimal antibody dilutions. To eliminate investigator effects introduced by manual gating, a non-biased
algorithm (OSA) for data-driven gating was developed. OSA-derived results correlated well with those obtained by
manual gating (r between 0.79 and 0.99) and outperformed other model-driven gating methods. Bland-Altman
plots confirmed the agreement of manual gating and OSA-derived results. A 1.33-fold increase (p=0.003) in the
number of positive cells after vaccination in a subgroup of pre-school children vaccinated with 100 μg GMZ2 was
present and in vaccinated adults from the same region we measured a baseline-corrected 1.23-fold,
vaccine-induced increase in mean fluorescence intensity of positive cells (p=0.03).
Conclusions: The current workflow advances detection and quantification of anti-plasmodial antibodies through
improvement of a bias-prone, low-throughput to an unbiased, semi-automated, scalable method. In conclusion,
this work presents a novel method for immunofluorescence assays in malaria research.
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Malaria is a major cause of morbidity and mortality in
endemic countries with African children carrying the
major burden of the disease. An efficacious malaria vac-
cine would be a cost-effective and easy-to-implement
intervention to complement current control strategies,
but until today no malaria vaccine is registered for rou-
tine use [1], although one product – RTS,S/AS01 – has
shown promising results in a clinical phase III study [2].
In contrast to vaccines containing pre-erythrocytic anti-
gens, such as RTS,S, vaccines directed against the asex-
ual blood stage are thought to act mainly through
antibodies (Abs). Hence, it is hypothesized that anti-
plasmodial Ab concentrations similar to those acquired
upon natural exposure are required to attain semi-
immunity, a type of non-sterile but robust immunity
that protects from clinical complications and excessive
parasite replication [1,3]. The main evidence for the role
of Abs in semi-immunity comes from studies where
purified Abs from African malaria-immune adults were
successfully used to treat non-immune malaria patients
[4,5] within Africa or, as an extension of this, in South-
East Asia [5]. The mechanisms, properties, and specifici-
ties of Abs that mediate protection in malaria, however,
remain unknown [3].
During clinical development of the malaria vaccine
candidate GMZ2 [6-8], it was noted that current assays
to monitor immunogenicity and pre-existing immunity
to malaria with intact parasites are bias-prone and diffi-
cult to standardize. Conventionally, most approaches are
based on enzyme-linked immunosorbent assay (ELISA)
using recombinant proteins or synthetic peptides as bait
antigen [9]. These could differ from their corresponding
native parasite counter-parts in their folding and post-
translational modifications, potentially altering the target
protein’s antigenic properties [3]. In addition, the degree
of parasite antigen exposure to the immune system (e.g.
the effects of localization in protein complexes or orga-
nelles) may be crucial for an effective anti-parasitic reac-
tion or as a correlate for successful vaccination. This
becomes even more important as second-generation,
multi-subunit and whole cell vaccines enter clinical de-
velopment [10]. As such, the use of microscopic
immunofluorescent antibody assay (IFA) to study Ab
concentrations against total parasite proteins expressed
in mature blood stage schizonts and merozoites using
native parasites [9,11] may provide important insights
into the Ab-mediated anti-plasmodial immune response.
Microscopic IFA however, has many setbacks; quantifi-
cation is done by determination of titers and quality
control remains problematic due to poor assay
standardization and potential investigator bias. Addition-
ally, the assay is not scalable and, therefore, investigation
of larger cohorts proves prohibitive [12]. On the otherside, in skillful hands, microscopic IFA is highly sensitive
and specific and provides information about the ability
of vaccine-induced Abs to bind to native parasite mole-
cules [9]. This being known, a scalable, sensitive, repro-
ducible, and quantitative assay based on flow cytometry,
a well-established and automatable technology, which is
widely available in developing countries [13], was pro-
posed to improve microscopy-based assays and allow for
high throughput measurements [14-16]. A major draw-
back of this approach is that flow cytometry data are
routinely analysed by manual gating, which is potentially
biased and inconsistent [15]. To overcome these chal-
lenges, a data-driven algorithm was developed to auto-
matically analyse flow cytometric data and a novel
workflow for a medium-throughput, sensitive, and reli-
able flow cytometry-based immunoassay for the detec-
tion and quantification of anti-plasmodial antibodies in
human serum is presented.
Methods
Study populations and serum samples
Serum samples from Day 0 (before vaccination) and Day
84 (4 weeks after the last of three vaccine administra-
tions) were collected from two clinical trials of GMZ2.
Details of the volunteers and vaccination schedules are
described elsewhere [7,8]. In brief, two double-blind,
randomized phase Ib clinical trials of GMZ2 were per-
formed in Lambaréné, Gabon; one enrolled adults [8],
the other pre-school children [7]. The trial involving
healthy Gabonese adults took place between July 2007
and August 2008. Twenty participants received 100 μg
GMZ2 adjuvanted with aluminium hydroxide (alum)
subcutaneously on Days 0, 28 and 56, whereas the 20
participants in the control group received rabies vaccine
intramuscularly at the same time points (Days 0, 28, and
56). The pediatric trial took place from September 2008
to October 2009 and involved 30 healthy pre-school
children aged 1 to 5 years. The children received three
doses of either rabies control vaccine (n = 10), 30 μg
GMZ2 (n = 10) or 100 μg GMZ2 (n = 10). The 3 doses
were administered one month apart (Days 0, 28 and 56)
by intramuscular injection.
Both studies were reviewed by the regional ethics
committee (Comité d‘Ethique Régional Indépendant de
Lambaréné; CERIL) and followed Good Clinical Practice
guidelines as defined by the International Conference on
Harmonization. All studies were conducted according
to the principles of the Declaration of Helsinki in its
5th revision.
Plasmodium falciparum culture, synchronization and
enrichment for late stages
The laboratory-adapted P. falciparum strain 3D7A,
obtained from the Malaria Research and Reference
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in complete medium (RPMI 1640, 25 mM HEPES,
2.4 mM L-glutamine, 50 μg/mL gentamicin and 0.5% w/v
Albumax). Confirmatory experiments were done using
the P. falciparum strain Dd2 obtained from the same
source. All cultures were maintained at 37°C in an atmos-
phere of 5% CO2 and 5% O2, with daily changes of
medium at 5% haematocrit and dilution with red blood
cells when the parasitaemia exceeded 5%.
Parasite cultures were synchronized at early ring stage
by treatment with 5% D-sorbitol (Sigma, St. Louis, USA)
for 10 min at 37°C. Isolation of synchronized P. falcip-
arum parasites (late trophozoite and schizont) was per-
formed using LD-MACS magnetic columns (Miltenyi
Biotec, Gladbach, Germany), as described previously, at
a parasitaemia of about 5% [17]. Following enrichment,
the purity of the parasite preparation was verified by
light microscopy and by flow cytometry after DNA stain-
ing with Hoechst 33342. In later experiments, Vybrant
DyeCycle violet stain (Invitrogen, Germany) replaced
Hoechst 33342.
Flow cytometry-based immunofluorescence assay
to detect anti-plasmodial antibodies
Preparation of parasites for cytometry was based on
a previously described fixation protocol [18]. Briefly,
P. falciparum culture enriched for late developmental
parasite stages were washed once in phosphate buffered
saline (PBS) and fixed by incubation in a combination
of PBS with 4% EM grade paraformaldehyde (Merck,
Germany) and 0.0075% EM grade glutaraldehyde
(Sigma-Aldrich, Germany) for 30 min. Fixed cells were
washed again in PBS and permeabilized for 10 min
in PBS/0.1% Triton-X-100 (TX100) (Sigma-Aldrich,
Germany). After another PBS wash step, free aldehyde
groups were reduced by incubating cells for 10 min
in PBS with 0.1 mg/ml sodium borohydride (Merck,
Germany). The preparation was washed again with PBS
and cells blocked in PBS/3% BSA. The cells were counted
using a haemocytometer (Neubauer–counting chamber)
and the pellet reconstituted in PBS to standardize the
number of cells used in the assay. As a modification of
the original protocol, all subsequent handling of cells in
1.5 ml sample tubes (Eppendorf, Hamburg, Germany)
was performed in 96-well round-bottom plates (Corning,
NY, USA) instead. To detect parasite-specific immuno-
globulin G (IgG), parasite suspension (2 μl of approx.
5.0 x 107 cells per ml) was added into each well of the
96-well plate resulting in a total volume of 100 μl of test
sera and control samples (each diluted in PBS/3%BSA)
and allowed to bind for 1 h at RT on a plate shaker. After
incubation, the cells were washed thrice with 150 μl of
PBS to remove excess unbound primary antibody. Subse-
quently, pellets were resuspended in 100 μl AlexaFluor488 goat anti-human IgG (Molecular Probes, Germany),
diluted in PBS/3%BSA, and incubated in the dark for 1
hour. Following three washes with PBS, cells were stored
at 4°C in the dark prior to cytometric analysis.
Antibody dilutions of both primary and secondary
antibodies used in the assay were pre-determined
through checkerboard titration experiments. The com-
bination of antibody dilutions that gave the best separ-
ation between negative and positive fluorescent parasites
was selected and used in subsequent experiments.
Furthermore, different dilutions of three second-step
AlexaFluor-conjugated goat anti-human IgG antibodies
as well as a non-conjugated anti-histidine rich protein 2
(HRP2) monoclonal IgM (used as positive control) were
tested. In addition, the shelf-life of parasite preparations
was estimated by re-assaying at Days 0, 3, 7, and 14,
since measurements from large clinical trials may take
more than one day and it would be preferable to be able
to use one parasite batch for such extended analyses.
Assay controls
Parasites stained i) without primary Ab and ii) with
serum from malaria naïve donors followed by the fluor-
escently labelled secondary antibody were used as nega-
tive controls. Positive control serum came from a pool
of serum from malaria-exposed semi-immune adults
living in Lambaréné, Gabon. As an additional positive
control, infected RBCs were stained for HRP2 with a
mouse monoclonal Ab (55A, anti-PfHRP2; Immunology
Consultants Laboratories, Newberg, USA) at a 20 μg/ml
concentration. Detection was performed using a 1/3,000
dilution of AlexaFluor 633 goat anti-mouse IgM (Invi-
trogen, Germany). Before analysing the cells with a flow
cytometer, fluorescence microscopy was done to verify
the effectiveness of the fluorescence stains and to verify
the cellular localization of Ab-bound parasite proteins.
Flow cytometry data acquisition and analysis
Parasite-infected cells were measured on a Becton
Dickinson FACS Canto II flow cytometer equipped with
the FACSDiva software version 6.1.2 (BD Biosciences,
San Jose, USA) and an attached Carousel loader in high
throughput mode. Relative fluorescence intensity of
each event was analysed using FACSDiva software ver-
sion 6.1.2 (BD Biosciences, San Jose, USA). Ab-reactivity
was expressed as percentage of positive fluorescent cells
(PPFC) and mean fluorescent intensity (MFI). Data
acquisition was stopped after 50,000 events for each
serum sample tested.
Model-based analysis of flow cytometry data
Several model-based algorithms have been developed to
automate the gating process thereby directly addressing



















































































Figure 2 Dose–response relationship in pooled serum.
Dilution series using a semi-immune serum pool. Bars show mean
fluorescence intensity (MFI) and connected squares percentage of
positive fluorescent cells (PPFC).
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based approaches, k-means [20] and an implementation
of the Expectation Maximization algorithm (EM) [21] were
tested on two experimental datasets. As part of this work,
the Overlap Subtraction Algorithm (OSA) was developed
and compared with model-based approaches. All described
methods were benchmarked using manual gating as a gold
standard. The OSA is implemented in the programming
language R and is available from the authors.
Design and mode of operation of the overlap
subtraction algorithm
The algorithm effectively mimics manual gating whenever
the gate is set with respect to an internal control. It detects
overlapping areas of two datasets (e.g. between a control
and the measurement of interest) in the two-dimensional
space and sets a gate at the border of the overlap. Cur-
rently, the algorithm is able to process one colour staining,
though it can be easily extended to process multicolour
staining. The algorithm accepts files in the flow cytometry
standard (FCS) 2.0 and 3.0 formats. MFI and PPFC are
computed and reported as output.
With flow cytometry typically a fixed number of cells
(e.g. 50,000) C are measured and analysed for each sam-
ple. Depending on the nature of the experiment, for each
measured cell ci ∈ C a vector of attributes a1. . .an can be
assigned, e.g., colour intensities for different dyes, for-
ward scatter (FSC), side scatter (SSC), etc. Generally,
each cell is represented by a data point in the two-
dimensional space, defined by the attributes a1 and a2.
The algorithm starts by partitioning the whole value
range for each attribute ai of interest in β equidistant inter-
vals, resulting in the vectors A1 and A2 of length β. The






Figure 1 Representative overlay showing the anti-plasmodial Ab resp
The best separation between the negative and positive fluorescent cells is
were treated as described in the methods. Note the increase in fluorescenc
incubated with serum diluted 1/32,000 (blue curve), 1/16,000 (orange curve
(red line) and the overall higher response after vaccination (Day 84).for the test and control sample respectively. Then the
values for Tij and Cij are calculated according to:
Tij ¼ cj j≥A1i∧ cj j < A1iþ1 þ cj j≥A2j∧ cj j < A2jþ1
Cij ¼ cj j≥A1i∧ cj j < A1iþ1 þ cj j≥A2j∧ cj j < A2jþ1 ð1Þ
Each entry in the matrices T and C stores the number of
data points |c| whose values for the attributes a1 and a2 lie
within a certain interval defined by the two vectors A1 and
A2. Next, the percentage of data points coming from the test
sample is determined according to the following formula:
Rij ¼ Tij= Cij þ Tij
  ð2Þ
Following this calculation, positive entries are selected,
i.e. entries in R that exceeds a certain threshold λ. ToDay 84  
FITC-A 
onses of a semi-immune individual vaccinated with GMZ2.
obtained when serum was diluted at 1/4,000. Test and control samples
e intensity as shown by the shift to the right when parasites were
), 1/8,000 (light green curve), 1/4,000 (green curve) or the control
Figure 3 Dose–response relationship in individual samples from semi-immune donors. A set of 40 paired Day 0 (left panel) and Day 84
(right panel) sera from the same semi-immune population as in Figure 2. Dose-dependent responses can be seen for both the mean
fluorescence intensity (MFI, upper panel) and percentage of positive fluorescent cell (PPFC, lower panel).
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meaning that 99 percent of the data points that were
counted for a particular entry come from the test sam-
ple. The correct gate is then set by finding the ωth occur-
rence of an entry with:
Zij≤λ ð3Þ
The parameter ω controls the sensitivity of the
method. In practice it is used to fine-tune the gate’s
distance to the negative control. By using low values
of ω the gate is set close to the border of the negative
control sample. Higher values of ω tend to produce
gates that have a bigger gap from the control sample.
After selection of relevant entries, the final gate is
determined by Loess Regression through the selected
coordinates.Statistical analysis of datasets from different populations
To detect differences in the MFI between groups due to
vaccination, a linear regression model was used. To ac-
count for baseline differences on Day 0, it was included
as covariate in the model (see Formula 4). Raw MFI
measurements were log10 transformed before use in fur-
ther analysis.
MFIday84 ¼ β0þβ1 MFIday0 þ β2  vaccine group ð4Þ
For PPFC measurements, which cannot be assumed to
follow a normal distribution, standard transformations
to achieve normality as proposed by Ahrens et al. [22]
did not work for both datasets. Therefore, log2 fold
changes between Day 0 and Day 84 were calculated.
Between-group differences in the children dataset were
tested by a one-way ANOVA followed by contrast
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ation within groups were tested by Student’s t-test.
Between-group comparisons and effects of vaccination
in the adult dataset were tested using a non-parametric
Wilcoxon test because even after transformation or calcu-
lation of ratios the data shows deviations from a normal
distribution. To compare results derived manually as well
as those obtained by automatic gating, Pearson’s correl-
ation coefficients were calculated using log10 transformed
Ab data measured as MFI. For PPFC comparisons Spear-
man’s rank correlation was used. Agreement between the
methods was further evaluated with the Bland-Altman
method [23]. The 95% confidence intervals for the mean
difference are indicated for all Bland-Altman plots. All ana-
lyses were done with R v.2.13.0 [24] and statistical signifi-
cance was defined as a two-sided p<0.05.
Results
Setup of assay parameters
To develop a standardized flow cytometric IFA to assess
the Ab-reactivity to fixed P. falciparum parasites, a pub-
lished fixation protocol [18] was adapted for use in flow
cytometry. The basis for optimization was the best dis-
crimination between positive and negative cells upon
incubation with a serum pool from semi-immune indivi-
duals and preserved integrity and morphology of the
cells. The final fixation and permeabilization conditions
are given in the methods. Titration experiments showed
that the use of semi-immune sera diluted at 1/4,000 fol-
lowed by a 1/3,000 dilution of AlexaFluor 488 conju-
gated goat anti-human IgG best discriminated between
negative and positive fluorescent cells (Figure 1).Table 1 Correlation of the four strategies employed for gatin
Gabonese adults (n = 37)a MFI day 0
k-means r = 0.95
r2 = 0.91
EM* r = 0.92
r2 = 0.85
Overlap subtraction r = 0.99
r2 = 0.99
Gabonese children (n = 28)b MFI day 0
k-means r = 0.71
r2 = 0.51
EM* r = 0.61
r2 = 0.38
Overlap subtraction r = 0.79
r2 = 0.62
*Expectation Maximization. r = Pearson’s correlation coefficient. r2 = Coefficient of d
expressed as mean fluorescence intensity (MFI) and percentage of positive fluoresc
data. aData excluded for 3 participants due to problems with data acquisition and i
been excluded from analysis for the same reasons as above. All p-values are significAssay validation procedure
Following protocol development the new flow
cytometry-based assay was validated using African semi-
immune serum samples. These sera were selected on the
basis of high anti-GMZ2 Ab-concentrations in ELISA.
To assess concentration-dependent responses in anti-
body levels, a semi-immune serum pool diluted from 1/
1,000 to 1/128,000 was used. Staining was specific (Fig-
ure 2) with only minimal cross-reaction to negative
samples.
In addition, experiments were performed using a set of
40 Day 0 and Day 84 sera from the GMZ2 phase Ib trial
in Gabonese adults serially diluted from 1/4,000 to 1/
32,000. As expected, the PPFC and MFI values were
dependent on the serum concentration (primary anti-
body) used in the assay and showed a consistent and
obvious dose-dependent response relation on the differ-
ent time points (Figure 3).
Application of model-based algorithms in flow cytometry
data analysis
Model-based gating algorithms were tested on two
datasets. Of these, only two methods (k-means and the
EM algorithm) tend to produce results that were compar-
able to those obtained by manual gating. They were
selected and their performance was further evaluated in
comparison to the manual gating strategy. Considering the
MFI, results from the two methods do significantly corre-
late (p<0.001) with those obtained manually in both data-
sets. In contrast, k-means produced non-significant results
for PPFC on Day 0 and 84 in the population of Gabonese
adults when compared to manual gating. In the pediatricg raw flow cytometry data
Manual gating
MFI day 84 PPFC day 0 PPFC day 84
r = 0.89 ρ = 0.04§ ρ = 0.14§
r2 = 0.79
r = 0.89 ρ = 0.89 ρ = 0.94
r2 = 0.80
r = 0.98 ρ = 0.99 ρ = 0.99
r2 = 0.96
MFI day 84 PPFC day 0 PPFC day 84
r = 0.76 ρ = −0.93 ρ = −0.88
r2 = 0.59
r = 0.64 ρ = 0.78 ρ = 0.81
r2 = 0.41
r = 0.83 ρ = 0.94 ρ = 0.96
r2 = 0.69
etermination. ρ = Spearman correlation coefficient. Ab (IgG) responses are
ent cell (PPFC). Correlations for MFI were calculated using log10 transformed
nability of some algorithms to set an appropriate gate. bTwo participants have
ant (p < 0.001) except for those marked with §.
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were even negatively correlated with those derived by
manual gating (ρ=-0.93 on Day 0, ρ=-0.89 on Day 84, both
p<0.001) (Table 1). Figures 4 and 5 show correlation
matrices from Gabonese adults and children comparing
the different analytical approaches using Day 0 PPFC mea-
surements. Despite the significant correlation in most
comparisons, Bland-Altman analyses show considerable
lack of agreement between k-means, EM and manual
gating for both, MFI and PPFC (Table 2). In both datasets
k-means tends to under-estimate whereas EM over-Figure 4 Correlation matrix of results from different flow cytometry d
Gabonese adults. The diagonal separates scatterplots (lower part) and the restimates the MFI using results from the manual gating as
reference. With regards to the PPFC among the children
population, k-means over-estimates it by 40% and 34%
on Day 0 and Day 84 respectively when compared to
the manual gating. The poor performance of these
methods on the datasets therefore motivated the
development of a new method for data-driven gating.
Since the different statistical approaches were not well-
suited for the data, an algorithmic approach (OSA) was
tested. In general, the algorithm produced results, which
compared well (p<0.0001) to manually gated dataata analysis methods: adults. PPFC measurements for Day 84 from
espective correlation coefficients (upper part).
Expectation
 Maximization







































Figure 5 Correlation matrix of results from different flow cytometry data analysis methods: children. PPFC measurements for Day 84
from Gabonese children. The diagonal separates scatterplots (lower part) and the respective correlation coefficients (upper part).
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time points, the correlation appeared to be stronger for
the adults (r ≥ 0.98) than for the children (r ≥ 0.79). In
contrast to the other methods, OSA shows a high
agreement with the results obtained from manual gating
(Table 2). The expected absolute error for the PPFC in
the semi-immune adults population is 30 and 60 times
lower than for EM and k-means, respectively (Table 2).
Figure 6 shows representative Bland–Altman plots with
95% limits of agreement (LOA). From all methods
tested, OSA shows the smallest 95% LOA in terms of
PPFC and MFI (Table 2).Application of the cytometric IFA on sera from
vaccinated subjects
The new method was applied to datasets from two
GMZ2 phase Ib trials to detect possible effects of vac-
cination on Ab response. Each dataset consists of
paired serum samples taken on Day 0 pre- and Day 84
post-vaccination. In total, 70 samples were analysed, 40
from semi-immune adults [8] and 30 from pre-school
children [7], both from Gabon. Figure 7 illustrates the
log2 fold changes in PPFC between Day 84 and Day 0
(baseline) responses of the different vaccine groups.
Among children, most volunteers in the two subgroups
Table 2 Bland-Altman analyses of the different data gating strategies
Manual gating
Gabonese adults (n = 37)a MFI day 0 MFI day 84 PPFC day 0 PPFC day 84
k-means 611 600.9 −0.04 −0.06
(464.3, 757.7) (350.5, 851.3) (−0.09, 0.005) (−0.12, -0.005)
Expectation −388.3 −328.7 0.02 0.01
Maximization (−600.2, -176.4) (−604.8, -52.7) (0.004, 0.04) (−0.003, 0.03)
Overlap subtraction −124.2 −98.1 0.006 −0.004
(−160.3, -88.2) (−143.4, -52.7) (0.003, 0.009) (−0.02, 0.001)
Gabonese children (n = 28)b MFI day 0 MFI day 84 PPFC day 0 PPFC day 84
k-means 198.6 205.8 −0.4 −0.34
(166.7, 230.6) (176.8, 234.8) (−0.49, -0.31) (−0.42, -0.27)
Expectation −208.9 −171.7 0.09 0.06
Maximization (−290.4, -127.3) (−214.5, -128.9) (0.03, 0.14) (0.05, 0.08)
Overlap subtraction 39.8 56.2 −0.04 −0.05
(25.1, 54.5) (43.6, 68.9) (−0.03, -0.05) (−0.06, -0.03)
Ab reactivity is expressed as mean fluorescence intensity (MFI) and percentage of positive fluorescent cell (PPFC). Data is given as mean differences of MFI
and PPFC values (lower and upper 95% confidence interval) between the different approaches. aData excluded for 3 participants due to problems with data
acquisition and inability of some algorithms to set an appropriate gate. bTwo participants have been excluded from analysis for the same reasons as above.
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84 (63% and 90% who received 30 μg and 100 μg
GMZ2, respectively). Out of all volunteers vaccinated
with GMZ2, only those who received 100 μg GMZ2
showed a significant increase (p=0.003) in their Ab
reactivity (1.33-fold, 95% CI: 1.15, 1.55), while no sig-
nificant increase was observed in the 30 μg group
(1.01-fold, 95% CI: 0.81, 1.27). Interestingly, 33% of all
participants in the rabies-vaccinated group had also a
higher response on Day 84. However, the remaining
six showed no or minimal increase in reactivity on
Day 84. As a consequence, no significant increase in
vaccine response was detected on Day 84 (1.09-fold,
95% CI: 0.94, 1.28). In contrast to the pre-school chil-
dren, no significant treatment effect on Day 84 was
detectable neither in the 100 μg GMZ2 (0.83-fold, 95%
CI: 0.71, 0.99) nor in the rabies control group (1.08-
fold, 95% CI: 0.97, 1.21) of the adult volunteers. In
addition, no differences between the vaccine groups
could be detected in both datasets. Interestingly, by
applying a linear regression model (Table 3) to the
log10 transformed MFI values, which adjusts for the
Ab reactivity on Day 0 (baseline), significantly higher
vaccine responses (p=0.03) were detected in the 100
μg GMZ2 group compared to the rabies group. In the
pre-school children population no significant between-
groups differences were detected.
Discussion
A well-studied reaction of the immune system to mal-
aria or vaccination with malaria vaccine candidates
is the induction of antigen-specific antibodies [25].
Implementation of assays that adequately detect levels ofantibodies induced by natural exposure or vaccination is
critical for monitoring immunogenicity. In this respect,
flow cytometric-based IFA techniques similar to the
approach described here have extensively been employed
to assess total IgG antibodies in the sera of humans
infected with protozoan parasites different from Plasmo-
dium [26-32]. With human malaria, some studies have
adapted related techniques - mainly to analyse responses
against plasmodial variant surface antigen [12,33-36],
which may have a role in parasite virulence or be used
as vaccine candidates.
Here, a novel approach for immunofluorescence
assays, which incorporates flow cytometry and offers
a rapid and reliable method of measuring total anti-
plasmodial Ab in human serum, is presented. In
contrast to conventional methods which utilize re-
combinant or synthetic peptides as antigen to assess
Ab responses [9], the improved workflow has several
advantages: i) Plasmodium parasites can be routinely
maintained in continuous in vitro cultures to produce
enough material for medium- to high-throughput
assays; ii) the use of whole-cell preparations of P. fal-
ciparum may preserve the target protein’s antigenic
properties better compared to soluble antigens [3],
which could be essential for an effective anti-parasitic
reaction to occur; and iii) the protein of interest is pre-
sented in its native context. Since fixed parasites
remained intact and stable for more than 2 weeks when
stored at 4°C, it is possible to analyse large sample
numbers over an extended period of time. Further-
more, data acquisition using a flow cytometer equipped
with a carousel or plate loader in high-throughput
mode ensures rapid and consistent analysis of samples
Figure 6 Representative Bland-Altman plots obtained by comparing different analytical approaches. The x-axis shows the mean of
both computationally and manually derived estimates for the PPFC and the y-axis the difference between them. The inner solid line represents
the mean difference for PPFC values while the outer dotted lines denote the lower and upper 95% limits of agreement between the
different strategies.

























Rabies GMZ2 30 µg GMZ2 100 µg
Figure 7 Changes in Ab levels of Gabonese adults and children following immunization with GMZ2. Data is expressed as log2 fold
change in PPFC between Day 0 and Day 84. P-values were obtained by a one-way ANOVA and the Wilcoxon test for the children and adults’
data respectively.
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variations. This greatly improves the assay reliability
when compared to the microscopic IFA technique,
where the effort is limited by the microscopist’s ex-
perience and speed and where substantial variation
among microscopists is common. The level of
standardization and throughput that is possible using
fully automated synthetic or recombinant peptides
cannot be attained with such an approach.
The conventional method of manual gating of flow
cytometry data is often investigator-dependent and diffi-
cult to standardize. To overcome these shortcomings
several statistical methods have been proposed in the lit-
erature. After applying them to two study datasets, even
the best performing ones (k-means and EM) showed
high error rates when compared to expert manual
gating. This disadvantage was remedied by the develop-
ment of a new algorithm (OSA), which, in contrast to
model-based methods, does not make any assumption
on the data distribution and mimics manual gating strat-
egies. OSA-derived results correlate well with those
derived by manual gating. As a data-driven algorithm,Table 3 Fold-changes in Ab reactivity after GMZ2
immunization of Gabonese adults and children
Study populations Mean (95% CI) P-value Comparison
Gabonese adults 1.23 (1.02, 1.48) 0.03 GMZ2 100 μg/Rabies
Gabonese children 1.04 (0.92, 1.17) 0.52 GMZ2 30 μg/Rabies
1.04 (0.93, 1.16) 0.48 GMZ2 100 μg/Rabies
1.0 (0.89, 1.13) 0.98 GMZ2 30 μg/100μg
Ab reactivity is presented as mean fluorescent intensity (MFI). Data is shown
as mean fold changes of the different comparisons (95% confidence interval).
P-values for MFI comparisons derived by linear regression model.OSA may not perform equally well in other experimen-
tal setups as it depends heavily on the data structure.
The whole workflow (cytometric IFA plus OSA) was
validated using samples from two vaccine studies in mal-
aria exposed adults and children who profoundly differ
in their baseline anti-plasmodial immunity and showed
a significant increase in specific Ab-reactivity against
the GMZ2 vaccine after vaccination [7,8]. By applying
the workflow, a moderate but significant increase in
vaccine-induced Abs response was observed based on
the PPFC, one month after a full immunization schedule
(Day 84) in a subgroup of children who received the
highest dose of GMZ2 (100 μg). Meanwhile, the effect
induced by a lower dose of the vaccine (GMZ2 30 μg)
was small and no significant treatment effect was detect-
able with this approach. A larger sample size may be
required to detect a significant effect in this subgroup.
In contrast to GMZ2-specific ELISA, which distin-
guishes GMZ2- from control-vaccinated children con-
sistently, cytometric IFA results represent the integrated
reactivity against all accessible parasite antigens after cell
permeabilization. This decreases the ability to detect a
specific signal but adds information about the size of the
effect in the context of naturally acquired immunity and
consequently complements antigen-specific methods.
Based on the PPFC outcome measure, no treatment
effect was observed in semi-immune adults immunized
with 100 μg GMZ2 (Figure 7). In contrast, a signifi-
cant vaccination effect was detected between the two
subgroups in the adult dataset when considering the
MFI (Table 3). From the statistical point of view, a possible
explanation for the contrasting observations in the two
outcome measures (MFI and PPFC) may relate to the fact
Ajua et al. Malaria Journal 2012, 11:367 Page 12 of 13
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than PPFC. Consequently, PPFC is the more conservative
measure and should be preferred in case of discordant
results when no mechanistic explanation is present. In the
present study, two different populations, which largely dif-
fer in their response pattern after vaccination were investi-
gated. Children with no or very little immunity develop
anti-plasmodial antibodies upon vaccination (increase
in PPFC), whereas in semi-immune adults a vaccine-
mediated boost of pre-existing anti-parasitic immune
response that translates into improved parasite recogni-
tion (increased MFI) is expected. Therefore, the results
are in line with the mechanistic concept of vaccination in
naïve and pre-exposed populations, respectively.
The relatively high pre-vaccination antibody levels
with specificities to different malaria parasite antigens
reported in the adults population [8] contribute much to
the large variation in the data. Therefore it is not surpris-
ing that a response to a single antigen is difficult to de-
tect. Nevertheless, results from this investigation
illustrate that a vaccine-induced increase in Ab- binding
to fixed Plasmodium parasites is detectable by this
methodology, demonstrating their potential functional
properties [34]. However, the assay may need further
adaptation for its use in subjects with no previous expos-
ure to malaria and low immune responses as was
observed in pilot experiments. IgG subclass-specific Ab
responses, especially the cytophilic antibodies known to
be associated with reduced risk of malaria [37,38], have
not been addressed in the present study but can be inte-
grated rather easily.
In summary, a new flow cytometry-based immunofluor-
escence assay is presented. It is a cheap, reliable and rapid
method to detect and quantify anti-plasmodial antibodies
in human sera and may be of value in malaria research. As
a next step this workflow will be applied to samples from
clinical phase II/III trials of malaria vaccine candidates to
characterize Ab-mediated immune responses and identify
correlates of vaccine-induced protection against malaria.
The non-biased data-driven computational analysis tool
(OSA) integrated in this methodology will be provided
under a general public license to the scientific community.
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